OncoTherics Poland has today successfully transformed from a Spółka z ograniczoną odpowiedzialnością (Sp. z o.o) to a Spółka akcyjna (S.A.) company as part of a …
Read more
OncoTherics presenting at #GPWInnovationDay 13th October 2021
OncoTherics CEO, Stefan Ogrodzinski, is due to showcase OncoTherics’ novel drug technology at the upcoming GPWInnovation day, sponsored by Trigon. The online conference aims to …
Read more
OncoTherics CEO presenting at the PACTT Pfizer Academy 27th February 2021
OncoTherics’ CEO, Stefan Ogrodzinski, will be presenting a short session about the UK biotech/life sciences ecosystem. The talk will compare the UK ecosystem to the …
Read more
OncoTherics’ CSO invited to the speak at Jagiellonian University 50th anniversary Faculty Celebration
The high-profile event will also recognise the award of the Nobel prize to Professor Robert Huber for his seminal works on hypoxia. Prof. Zbigniew Madeja, …
Read more
OncoTherics Poland secures 12M PLN grant funding
Oncotherics Poland Sp. zo.o. is delighted to announce that it has secured a 11.7M PLN grant as part of the regional operational program of the …
Read more
OncoTherics Poland updates progress at LSBC 2019, Krakow
Read more
OncoTherics wins “best pitch” at LSBC Investor Conference, Krakow
OncoTherics is delighted to have won the “best company presentation” competition at the 2018 Central European Life Science Investment Conference this October, in Krakow, Poland. …
Read more
OncoTherics forms wholly owned subsidiary in Poland
OncoTherics is delighted to announce the formation of OncoTherics Poland Sp.Zo.o., a wholly owned subsidiary of OncoTherics Limited, formed specifically to pursue the development of …
Read more
OncoTherics wins RESI Innovation Challenge competition
OncoTherics has won an International Innovation Challenge competition, and a chance to “pitch” at the upcoming RESI Investor conference this April, to be held at …
Read more
OncoTherics signs MoU with University Health Network (UHN), Toronto
OncoTherics and University Health Network (UHN), Toronto have signed a memorandum of understanding to progress the development of the company’s novel hypoxia-activated cancer drugs at …
Read more